|Leave a Message or Start an on-line Chat
The creation of the CTNNB1 recombinant monoclonal antibody involves a precise and systematic process to ensure its exceptional quality and specificity. It begins with the isolation of B cells from the spleen of an immunized animal, where the synthesized peptide derived from human beta-Catenin acts as the immunogen. RNA is then extracted from the B cells and converted into cDNA through reverse transcription. The CTNNB1 antibody genes are amplified using specific primers targeting the antibody constant regions and inserted into an expression vector. This vector is subsequently introduced into host cells through transfection, allowing for the production of the CTNNB1 recombinant monoclonal antibody. After a period of cell culture, the antibody is harvested from the cell culture supernatant and subjected to a meticulous purification process utilizing affinity chromatography. This ensures the obtainment of a highly purified form of the CTNNB1 recombinant monoclonal antibody suitable for diverse applications. Rigorous characterization assays, including ELISA and IHC analysis, are performed to validate the antibody's specificity and functionality in detecting human CTNNB1 protein. The comprehensive production process guarantees the development of a reliable and effective CTNNB1 recombinant monoclonal antibody, serving as a valuable tool in research pertaining to CTNNB1.
There are currently no reviews for this product.